Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro.
暂无分享,去创建一个
[1] R. Stouffer,et al. Modulation of membrane fluidity in the primate (Macaca mulatta) corpus luteum: correlation with changes in gonadotropin binding. , 1985, Endocrinology.
[2] R. Knazek,et al. Effects of dietary essential fatty acids on murine mammary gland development. , 1981, Cancer research.
[3] H. Moser,et al. The design of a diet restricted in saturated very long-chain fatty acids: therapeutic application in adrenoleukodystrophy. , 1984, The American journal of clinical nutrition.
[4] M. Schramm,et al. Fatty acids as modulators of membrane functions: catecholamine-activated adenylate cyclase of the turkey erythrocyte. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Shinitzky,et al. Microviscosity parameters and protein mobility in biological membranes. , 1976, Biochimica et biophysica acta.
[6] E. Zackai,et al. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. , 1986, American journal of medical genetics.
[7] T. E. Thompson,et al. Fluorescence depolarization studies of phase transitions and fluidity in phospholipid bilayers. 2 Two-component phosphatidylcholine liposomes. , 1976, Biochemistry.
[8] A. Moser,et al. A new dietary therapy for adrenoleukodystrophy: Biochemical and preliminary clinical results in 36 patients , 1987, Annals of neurology.
[9] J. Menkes,et al. Adrenoleukodystrophy: Accumulation of cholesterol esters with very long chain fatty acids , 1977, Neurology.
[10] Y. Barenholz,et al. Fluidity parameters of lipid regions determined by fluorescence polarization. , 1978, Biochimica et biophysica acta.
[11] J. Dave,et al. Prostaglandin I2 modifies both prolactin binding capacity and fluidity of mouse liver membranes. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[12] H. Moser,et al. Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. , 1982, The Johns Hopkins medical journal.
[13] J. Dave,et al. Modulation of prolactin binding sites in vitro by membrane fluidizers. II. Age-dependent effects on rat ventral prostatic membranes. , 1984, Biochimica et biophysica acta.
[14] P. Watkins,et al. Adrenoleukodystrophy , 1986, Neurology.
[15] H. Moser,et al. Adrenoleukodystrophy: Survey of 303 cases: Biochemistry, diagnosis, and therapy , 1984, Annals of neurology.
[16] W. Engel,et al. Abnormalities in cultured muscle and peripheral nerve of a patient with adrenomyeloneuropathy. , 1979, The New England journal of medicine.
[17] J. Dave,et al. Arachidonic acid, bradykinin and phospholipase A2 modify both prolactin binding capacity and fluidity of mouse hepatic membranes. , 1981, Biochemical and biophysical research communications.
[18] H. Moser,et al. Adrenoleukodystrophy: Impaired Oxidation of Very Long Chain Fatty Acids in White Blood Cells, Cultured Skin Fibroblasts, and Amniocytes , 1984, Pediatric Research.
[19] G. Radda,et al. The relation between lipid mobility and the specific hormone binding of thyroid membranes. , 1975, The Biochemical journal.
[20] J. Dave,et al. Indomethacin causes a simultaneous decrease of both prolactin binding and fluidity of mouse liver membranes. , 1981, Prostaglandins and medicine.
[21] K. Suzuki,et al. FATTY ACID ABNORMALITY IN ADRENOLEUKODYSTROPHY , 1976, Journal of neurochemistry.
[22] R. Knazek,et al. Dietary Essential Fatty Acids Are Required for Maintenance and Induction of Prolactin Receptors , 1979, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[23] W. Rizzo,et al. Adrenoleukodystrophy: Dietary oleic acid lowers hexacosanoate levels , 1987, Annals of neurology.
[24] J. Dave,et al. Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. , 1983, The Journal of clinical investigation.